A nemaline myopathy–linked mutation inhibits the actin-regulatory functions of tropomodulin and leiomodin
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2315820120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Lauren E Schultz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine and Sarver Molecular Cardiovascular Research Program, The University of Arizona, Tucson, AZ 85724. Hauptthemen laut MEDLINE: Actins, Myopathies, Nemaline. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Actin is a highly expressed protein in eukaryotic cells and is essential for numerous cellular processes. In particular, efficient striated muscle contraction is dependent upon the precise regulation of actin-based thin filament structure and function. Alterations in the lengths of actin-thin filaments can lead to the development of myopathies. Leiomodins and tropomodulins are members of an actin-binding protein family that fine-tune thin filament lengths, and their dysfunction is implicated in muscle diseases. An Lmod3 mutation [G326R] was previously identified in patients with nemaline myopathy (NM), a severe skeletal muscle disorder; this residue is conserved among Lmod and Tmod isoforms and resides within their homologous leucine-rich repeat (LRR) domain. We mutated this glycine to arginine in Lmod and Tmod to determine the physiological function of this residue and domain. This G-to-R substitution disrupts Lmod and Tmod’s LRR domain structure, altering their binding interface with actin and destroying their abilities to regulate thin filament lengths. Additionally, this mutation renders Lmod3 nonfunctional in vivo. We found that one single amino acid is essential for folding of Lmod and Tmod LRR domains, and thus is essential for the opposing actin-regulatory functions of Lmod (filament elongation) and Tmod (filament shortening), revealing a mechanism underlying the development of NM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Medicine and Sarver Molecular Cardiovascular Research Program, The University of Arizona, Tucson, AZ 85724.
- Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA 99164.
- Department of Medicine, Cardiovascular Research Institute, Icahn School of Medicine, New York, NY 10029.
ORCID-Profile: Lauren E Schultz, Mert Colpan, Alla S Kostyukova
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
- American Heart Association
Zitieren
APA
Schultz, L. E., Colpan, M., Smith, G. E., Mayfield, R. M., Larrinaga, T. M., Kostyukova, A. S., & Gregorio, C. C. (2023). A nemaline myopathy–linked mutation inhibits the actin-regulatory functions of tropomodulin and leiomodin. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2315820120
Vancouver
Schultz LE, Colpan M, Smith GE, Mayfield RM, Larrinaga TM, Kostyukova AS, et al. A nemaline myopathy–linked mutation inhibits the actin-regulatory functions of tropomodulin and leiomodin. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2315820120
BibTeX
@article{Schultz2023,
author = {Schultz, Lauren E and Colpan, Mert and Smith, Garry E and Mayfield, Rachel M and Larrinaga, Tania M and Kostyukova, Alla S and Gregorio, Carol C},
title = {A nemaline myopathy–linked mutation inhibits the actin-regulatory functions of tropomodulin and leiomodin},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2315820120}
}
EUVIMED